



# R&D & Innovation in Kyowa Kirin

## Areas of interest



Cutting-edge biotechnology  
centered on antibody  
engineering technology



## Challenging the creation of new value in R&D

# Initiatives for expanding the opportunities to create value unique to Kyowa Kirin

- **Initiatives and innovation through internal activities + collaborations**
  - Axcelead, InveniAI, SBI Biotech
  - **Next generation antibody technology**, Nucleic acid therapeutics, Small molecule drug discovery, Regenerative medicine
- **Foster next generation product candidates (global products, etc.)**
  - KHK4083, KW-6356, ME-401, RTA 402, KHK7791...

### Technology strategy

Utilize next generation antibody technology and diverse modalities to build a platform that will support revolutionary new pharmaceuticals

### Disease strategy

Utilize the accumulated knowledge and technology to change the lives of patients by providing unique value for UMN



# I & A



antibody  
 protein  
 small molecule


© New Molecular Entity

Updated since Dec. 31, 2019

Updated since Jun 30, 2020  
 As of Sep. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Stage					[In-House or Licensed] Remarks	
		Ph I	Ph II	Ph III	Filed	Approved		
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody							[Kirin-Amgen]
©KHK4083 Injection	Anti-OX40 Fully Human Antibody							[In-House] POTELLIGENT® Human Antibody-Producing Technology
©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody							[In-House] Human Antibody-Producing Technology Jointly Developed with Astellas

# CNS



Code Name Generic Name Formulation	Mechanism of Action	Stage					[In-House or Licensed] Remarks	
		Ph I	Ph II	Ph III	Filed	Approved		
KW-6002 Istradefylline Oral	Adenosine A <sub>2A</sub> Receptor Antagonist							[In-House]
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody							[In-House] POTELLIGENT®
©KW-6356 Oral	Adenosine A <sub>2A</sub> Receptor Antagonist							[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody							[Immunas Pharma]

# But this is not all...



April 14, 2020

## MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

- MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharing
- Kyowa Kirin obtains exclusive commercialization rights ex-U.S.; MEI to receive escalating tiered royalty payments on ex-U.S. sales
- MEI to receive \$100 million in an upfront cash payment and is eligible to receive up to an additional \$582.5 million based on the achievement of specified development, regulatory and commercial milestones
- MEI to host conference call on April 14 at 8:00 a.m. ET

SAN DIEGO, and TOKYO, April 14, 2020 – MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today jointly announced that the companies have entered into a global license, development and commercialization agreement to further develop and commercialize MEI's ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kδ), in clinical development for the treatment of B-cell malignancies. MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S.

ME-401 is being studied in the ongoing Phase 2 TIDAL clinical trial evaluating patients with relapsed or refractory follicular lymphoma which, subject to results, may support an accelerated approval of a marketing application with the U.S. Food and Drug Administration (FDA). An ongoing Phase 1b study is evaluating ME-401 as a monotherapy and in combination with rituximab or zanubrutinib in patients with B-cell malignancies. Also, a Phase 1 study was initiated in 2019 evaluating ME-401 as a monotherapy in patients with indolent B-cell malignancy in Japan.



### InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration

- Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin's antibody technology
  - Kyowa Kirin will select multiple programs to advance into clinical development
- InveniAI® is eligible to receive an upfront payment, development and commercial milestones, and royalties

GUILFORD, Connecticut, and TOKYO, Japan, December 9, 2020, InveniAI® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, are pleased to announce they have expanded their collaboration agreement to harness the power of InveniAI's AI-platform, AlphaMeld®, for novel target discovery.

InveniAI and Kyowa Kirin have been collaborating since 2018, to maximize Kyowa Kirin's portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications utilizing AlphaMeld®. Through this expansion, Kyowa Kirin will leverage AlphaMeld® for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies that address the enduring unmet needs of patients across multiple diseases. Under the terms of the agreement, Kyowa Kirin will select multiple programs to advance into clinical development.

### News Release

October 2, 2020

## Axcellead and Kyowa Kirin Started an Innovative Collaboration in Small-Molecule Drug Development

Tokyo, Japan, October 2, 2020 ---Axcellead Drug Discovery Partners Inc. (Axcellead, President: Yoshinori Ikeura) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announce that the companies have started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform.

By integrating Axcellead's broad range of small-molecule drug discovery technologies and experience with Kyowa Kirin's innovative drug discovery technologies, the companies will be able to build a novel small-molecule drug discovery technology platform. Utilizing this technology platform the companies aim to expand R&D pipeline of Kyowa Kirin through the discovery of multiple innovative drug candidates for diverse targets that were inaccessible so far.

"Our mission is to contribute to the discovery of innovative drugs as the best partner for people engaged in drug discovery, based on the technology and know-how we have accumulated through our research in the pharmaceutical industry and the vast amount of drug discovery data we have collected," said Yoshinori Ikeura, President of Axcellead. "We are delighted to be able to develop fundamental technologies that will open up a new era of small-molecule drugs and contribute to the discovery of drugs for a variety of previously inaccessible drug targets."